Jaguar Health (FRA:1JA1) Research & Development: €21.57 Mil (TTM As of Mar. 2026)


FRA:1JA1 Jaguar Health Inc FRA:1JA1
22 GF Score
Price €0.00
! 3 Warning Signs
View Full Analysis

What is Jaguar Health Research & Development?

Jaguar Health FRA:1JA1 22 Research & Development is €21.57 Mil as of Mar. 2026. GuruFocus rates FRA:1JA1 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Jaguar Health's Research & Development for the three months ended in Mar. 2026 was €3.40 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €21.57 Mil.

Jaguar Health  (FRA:1JA1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Jaguar Health Research & Development Related Terms

Jaguar Health Research & Development Historical Data

* Premium members only.

The historical data trend for Jaguar Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jaguar Health Research & Development Chart

Jaguar Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.35 16.66 17.05 15.80 21.32

Jaguar Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.45 2.83 3.12 12.22 3.40
FRA:1JA1
22GF Score
Jaguar Health Inc FRA:1JA1
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jaguar Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €21.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €21.57 Mil mean?
Jaguar Health (FRA:1JA1) has a Research & Development of €21.57 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Jaguar Health and its competitors.
Is Jaguar Health's Research & Development too high?
Jaguar Health's current Research & Development is €21.57 Mil. Overall, Jaguar Health has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Jaguar Health's Research & Development compare to BBLG and VBIO?
Jaguar Health's Research & Development of €21.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Jaguar Health and its competitors. Jaguar Health's current Research & Development is €21.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaguar Health stock overvalued right now?
Jaguar Health (FRA:1JA1) has a current Research & Development of €21.57 Mil. The current Research & Development is €21.57 Mil. Jaguar Health's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Jaguar Health (FRA:1JA1), the current Research & Development is €21.57 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jaguar Health Business Description

Other Exchanges JAGX:USA
Address 200 Pine Street, Suite 400, San Francisco, CA, USA, 94104
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
22GF Score

Get the complete analysis for FRA:1JA1

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00
Price